Table 3.

Values of intra-operative blood loss according to pre-operative factors

		Intra-operative blood loss (mL)	P-value
Age	≤60 years	500 (50–2400)	0.873
	>60 years	500 (50–3000)
Gender	Male	500 (50–3000)	<0.001
	Female	375 (50–1350)
BMI (kg/m2)	<30	450 (50–3000)	0.026
	≥30	650 (50–2000)
ASA score	I-II	500 (50–3000)	0.582
	III	400 (200–2900)
Diabetes mellitus	No	500 (50–3000)	0.572
	Yes	450 (50–2900)
Malignant disease	No	400 (50–1400)	0.386
	Yes	500 (50–3000)
Hepatocellular carcinoma	No	442 (50–3000)	0.014
	Yes	600 (50–2000)
Liver metastases	No	500 (50–2400)	0.205
	Yes	500 (50–3000)
Previous cholecystectomy	No	500 (50–3000)	0.860
	Yes	400 (200–900)
Re hepatectomy	No	500 (50–3000)	0.790
	Yes	500 (100–2900)
Pre-operative chemotherapya	No	500 (50–3000)	0.177
	Yes	400 (50–2900)
Pre-operative PVE	No	500 (50–3000)	0.586
	Yes	525 (50–1700)
Tumour size	≤8 cm	500 (50–3000)	0.037
	>8 cm	550 (50–2900)
Concomitant surgery	No	500 (50–2900)	0.435
	Yes	400 (150–3000)
Liver fibrosisb	F0	450 (50–3000)	0.111
	F1-F2	500 (100–1700)
Steatosis ≥30%	No	450 (50–2900)	0.013
	Yes	625 (200–3000)

^aThe proportion of patients with pre-operative chemotherapy was calculated in the subgroup of patients with liver metastases. Only preoperative chemotherapy performed less than 12 weeks before surgery was considered as having a potential impact on the intra- and post-operative outcome.⁶³

^bAccording to the METAVIR classification.²⁰

BMI, body mass index, ASA, American Society of Anaesthesiologists; PVE, portal vein embolization.